Earnings Presentation Materials for the First Quarter of the Fiscal Year Ending March 2027 | Nitta Gelatin Inc. (4977) timely disclosure

Worth reading

44Recurring

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

755

¥ million

Wording

Conditional

How definitive the wording is.

Contents of this document

Earnings presentationFirst quarter of the fiscal year ending March 20274 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥9,893 million+8.3%

Operating profit¥1,184 million-5.5%

Ordinary income¥1,271 million+1.8%

Net income¥690 million+10.4%

Operating profit margin

Rate12

Year-on-year change (points)-1.8

Results for the three months of the current quarter

Net Sales

¥9,893 million

Gross profit

¥2,772 million

Operating profit

¥1,184 million

Ordinary income

¥1,271 million

Profit attributable to owners of parent for the quarter

¥690 million

Full-year earnings forecast

Net Sales

¥43,000 million

Gross profit

¥12,000 million

Operating profit

¥4,700 million

Ordinary income

¥4,800 million

Profit attributable to owners of the parent

¥2,400 million

Operating profit margin

10.9 %

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Net Sales23.0%

Gross profit23.1%

Operating profit25.2%

Ordinary income26.5%

Profit attributable to owners of parent for the quarter28.8%

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Progress at each profit level is on track

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Net Sales

Gelatin

¥398 million

Collagen peptides

¥281 million

Food Materials

¥60 million

Biomedical

¥14 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

US dollars

Full-year forecast for the fiscal year ending March 2027¥150

Canadian dollar

Full-year forecast for the fiscal year ending March 2027¥109.66

Indian rupee

Full-year forecast for the fiscal year ending March 2027¥1.71

Segment results

Gelatin

Revenue for the first quarter of the fiscal year ended March 2026

¥6,663 million

Revenue for the first quarter of the fiscal year ending March 2027

¥7,062 million

Year on year against the same period last year+6.0%

Collagen peptides

Revenue for the first quarter of the fiscal year ended March 2026

¥1,586 million

Revenue for the first quarter of the fiscal year ending March 2027

¥1,868 million

Year on year against the same period last year+17.8%

Food Materials

Revenue for the first quarter of the fiscal year ended March 2026

¥791 million

Revenue for the first quarter of the fiscal year ending March 2027

¥852 million

Year on year against the same period last year+7.7%

Biomedical

Revenue for the first quarter of the fiscal year ended March 2026

¥96 million

Revenue for the first quarter of the fiscal year ending March 2027

¥111 million

Year on year against the same period last year+14.9%

Contents of this document
Item	Details
Document type	Earnings presentation
Fiscal Period Covered	First quarter of the fiscal year ending March 2027
Net Sales	¥9,893 million (YoY +8.3%)
Operating profit	¥1,184 million (YoY -5.5%)
Ordinary income	¥1,271 million (YoY +1.8%)
Net income	¥690 million (YoY +10.4%)
Operating profit margin	Rate 12 / Year-on-year change (points) -1.8
Results for the three months of the current quarter	Net Sales ¥9,893 million / Gross profit ¥2,772 million / Operating profit ¥1,184 million / Ordinary income ¥1,271 million / Profit attributable to owners of parent for the quarter ¥690 million
Full-year earnings forecast	Net Sales ¥43,000 million / Gross profit ¥12,000 million / Operating profit ¥4,700 million / Ordinary income ¥4,800 million / Profit attributable to owners of the parent ¥2,400 million / Operating profit margin 10.9 %
Progress against full-year forecast	Net Sales 23.0% / Gross profit 23.1% / Operating profit 25.2% / Ordinary income 26.5% / Profit attributable to owners of parent for the quarter 28.8%
Self-assessment against the plan	Progress at each profit level is on track
Segment results	Gelatin Revenue for the first quarter of the fiscal year ended March 2026 ¥6,663 million / Revenue for the first quarter of the fiscal year ending March 2027 ¥7,062 million / Year on year against the same period last year +6.0% / Collagen peptides Revenue for the first quarter of the fiscal year ended March 2026 ¥1,586 million / Revenue for the first quarter of the fiscal year ending March 2027 ¥1,868 million / Year on year against the same period last year +17.8% / Food Materials Revenue for the first quarter of the fiscal year ended March 2026 ¥791 million / Revenue for the first quarter of the fiscal year ending March 2027 ¥852 million / Year on year against the same period last year +7.7% / Biomedical Revenue for the first quarter of the fiscal year ended March 2026 ¥96 million / Revenue for the first quarter of the fiscal year ending March 2027 ¥111 million / Year on year against the same period last year +14.9%
Breakdown of Factors Affecting the Change	Net Sales Gelatin ¥398 million / Collagen peptides ¥281 million / Food Materials ¥60 million / Biomedical ¥14 million
Assumptions Underlying the Business Outlook	US dollars Full-year forecast for the fiscal year ending March 2027 ¥150 / Canadian dollar Full-year forecast for the fiscal year ending March 2027 ¥109.66 / Indian rupee Full-year forecast for the fiscal year ending March 2027 ¥1.71

Items this document does not state (17)

Gross Profit MarginSelling, general and administrative expensesKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased mainly because sales of gelatin and collagen peptides remained firm in North America. Although profitability declined slightly from the previous fiscal year, it remained within the range assumed in the initial forecast. In non-operating income and expenses, the foreign exchange loss recorded in the previous fiscal year turned into a foreign exchange gain.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.